Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study

Colin S. Tan1,2,3,4*, Louis W. Lim1,2†, Wei Kiong Ngo1,2, Pandiyan Pannirselvam2,3, Clarence See2,3, Wai Kitt Chee2 and Nakul Saxena5

Abstract

Background: To determine the frequency of persistent disease activity following 3 loading doses of anti-vascular endothelial growth factor (VEGF) agents, and the anatomic and demographic predictors of early persistent disease activity among patients with neovascular age-related macular degeneration (nAMD).

Methods: In a retrospective real-world cohort study, 281 consecutive patients with nAMD were reviewed at baseline and after 3 anti-VEGF injections for pre-defined indicators of disease activity. Optical coherence tomography (OCT) features such as subretinal fluid, intraretinal cysts and intraretinal fluid were assessed by reading-center certified graders. Multiple logistic regression was performed on demographic and anatomic factors.

Results: At month 3, 66.1% of patients had persistent disease activity. The best-corrected visual acuity (BCVA) improvement was 0.16 LogMAR for those with no disease activity compared to 0 for patients with persistent activity ($p < 0.001$). The significant risk factors for persistent activity at 3 months were male gender (odds ratio [OR] 0.54, 95% confidence interval [CI] 0.32–0.93, $p = 0.025$), intraretinal cysts at baseline (OR 2.95, 95% CI 1.67–5.20, $p < 0.001$) and subretinal fluid at baseline (OR 3.17, 95% CI 1.67–5.20, $p < 0.001$). At 3 months, 58% of patients had features of activity on OCT. Patients with intraretinal cysts and intraretinal fluid at baseline had worse BCVA at month 3 compared to patients without these OCT features (0.69 vs. 0.43, $p < 0.001$, and 0.62 vs. 0.43, $p < 0.001$, respectively).

Conclusions: In a real-world study, 66.1% of nAMD patients have persistent disease activity after the initial loading dose, with poorer BCVA compared to those without. Baseline OCT features (intraretinal cysts and subretinal fluid) are useful predictors of persistent disease activity at month 3.

Keywords: Anti-VEGF, Neovascular age related macular degeneration, Polypoidal choroidal vasculopathy, Persistent disease activity

* Correspondence: Colintan_eye@yahoo.com.sg
† Colin S. Tan and Louis W. Lim contributed equally to this work.
1Fundus Image Reading Centre, National Healthcare Group Eye Institute, Singapore, Singapore
2National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore
3Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Age-related macular degeneration (AMD) is the leading cause of blindness among individuals older than 50 years in developed nations [1, 2], and may result in severe visual loss.

Advances in imaging technology, especially optical coherence tomography (OCT), have revolutionized AMD diagnosis and treatment algorithms [3]. Features such as intra-retinal fluid and sub-retinal fluid detected on OCT are assessed to determine disease activity and treatment response.

Studies have reported that the initial treatment response to anti-vascular endothelial growth factor (VEGF) agents may be predictive of the long-term clinical outcome [4, 5]. However, many randomized controlled clinical trials, as well as non-randomized, single-arm studies, typically report the main outcomes at 12 months. Few studies have focused on the early outcomes after the initial 3 loading doses of anti-VEGF. Another key knowledge gap is the factors which predict the initial, early response to treatment.

Determining the proportion of nAMD patients with persistent disease activity, and the predictors of persistent disease activity following the initial loading dose of anti-VEGF, will help clinicians identify potential high-risk patients for whom a more rigorous treatment and follow-up regimen can be established.

The objective of this study is to determine the proportion of patients with persistent disease activity following 3 loading doses of the same anti-VEGF, and the demographic and anatomic predictors of persistent disease activity.

Methods
In a single-centre retrospective cohort study, consecutive treatment-naive patients diagnosed with either nAMD or Polypoidal Choroidal Vasculopathy (PCV) at the National Healthcare Group Eye Institute, Tan Tock Seng Hospital between 1 January 2014 to 31 October 2017 were reviewed. Treatment outcomes were assessed after 3 monthly loading doses (defined as 3 injections within 90 days of the first injection) of anti-VEGF drugs (Ranibizumab, Bevacizumab or Aflibercept). Patients were reviewed within 4 weeks of the third anti-VEGF injection.

All patients underwent a spectral domain OCT scan (Spectralis, Heidelberg Engineering, Heidelberg, Germany) prior to and after receiving the 3 loading doses of anti-VEGF. On presentation, fluorescein angiography (FA) and indocyanine green angiography (ICGA) were performed on all patients to establish the diagnosis and to distinguish between nAMD and PCV [6–10].

Patients were excluded from the study if they received any treatment for nAMD or PCV prior to recruitment or if they underwent verteporfin photodynamic therapy. Patients were also excluded if cataract surgery was performed during the study period. Other disease conditions that may affect best-corrected visual acuity (BCVA) or central retinal thickness measurements, such as diabetic retinopathy, diabetic macular edema, retinal vein occlusion, epiretinal membrane and glaucoma, were also excluded.

The primary outcome measure was the proportion of patients with disease activity following 3 loading doses of anti-VEGF injections. Potential predictors of disease activity assessed were patient demographics, comorbidities, baseline BCVA, baseline OCT features and retinal thickness.

The study was approved by the institutional review board of the National Healthcare Group and conformed to the tenets of the Declaration of Helsinki.

Grading of retinal images were performed by trained graders from the Fundus Image Reading Center, National Healthcare Group Eye Institute, using standardized grading protocols. The diagnosis of PCV and its differentiation from nAMD was performed using the diagnostic criteria described in the EVEREST and EVEREST II studies [6–12]. Central subfield retinal thickness (CSFT) was measured using the proprietary Heidelberg viewer software [13–18]. Trained graders screened each OCT B-scan for segmentation errors and manually adjusted these when errors were present. The presence of intraretinal fluid, cysts and subretinal fluid was manually graded. Intraretinal cysts was defined as areas of round or oval hyporeflectivity with clear borders located within the retinal tissue. Intraretinal fluid was defined as widening of the retinal bands compared to normal, healthy retina. In our clinical practice, FA and ICGA are not routinely performed after the initial 3 treatments, unless there is a specific clinical indication, such as worsening of clinical findings.

Using both OCT and visual acuity criteria, we defined persistent disease activity as

1) Decrease in BCVA of ≥5 letters compared with baseline; or
2) Decrease in BCVA of ≥3 letters and CSFT increase ≥75 μm compared with baseline; or.
3) Any presence of intraretinal fluid / subretinal fluid / cysts at week 12.

Overall, 296 patients were screened, with 281 included for analysis. Of the 15 patients who were excluded, 13 patients had ungradable images, 1 had a diagnosis of cystoid macular oedema and 1 patient had no follow up scans at month 3.

Statistical analysis was performed using SPSS version 16 (SPSS Inc., Chicago, IL, USA). X² tests were used to compare the proportions of various groups, and
Results
The mean age of the 281 patients was 77.7 years (range, 54 to 98, SD ± 9.0), with 168 males (59.8%) and 113 females (40.2%) (Table 1). The majority of patients had nAMD (221 patients, 78.6%) while the remaining 60 (21.4%) were diagnosed with PCV. The proportion of anti-VEGF used was 60.1% bevacizumab, 27.8% ranibizumab, and 12.1% aflibercept.

On initial presentation, all patients had features of disease activity. At 3 months, after the initial 3 doses of anti-VEGF drugs, 179 patients (66.1%) were found to have persistent activity, based on the pre-defined criteria of OCT findings and/or changes in BCVA.

There were no significant differences in baseline demographics, BCVA or central retinal thickness between the patients with persistent disease activity at 3 months compared to those without disease activity at 3 months (Table 2).

The improvement in visual acuity and CSFT was greater among the group with no persistent activity compared to those with persistent disease activity. The mean visual acuity was 54.5 letters (Snellen equivalent of 6/24) at baseline and improved to 57.5 letters (Snellen equivalent of 6/18) at 3 months (p = 0.02). Among patients with no disease activity at month 3, the mean visual acuity (VA) improved by 8 letters, compared to 0.01 letters in patients with persistent disease activity (p < 0.001).

Overall, CSFT was 442.4 μm (range, 188 to 1534, SD ± 193.0), and decreased to 349.1 μm (range, 150 to 1534, SD ± 143.9) at month 3 (p < 0.001). Among patients with no disease activity at month 3, the mean CSFT improved by 93.0 μm, compared to 88.8 μm in eyes with persistent disease activity (p = 0.816).

Risk factors for persistent disease activity
Univariate logistic regression showed that male gender, intraretinal cysts and subretinal fluid were predictive of disease activity at week 12 (Table 3). Performing stepwise multiple logistic regression analysis, the same factors were found to be predictive of persistent disease activity at 3 months: male gender (odds ratio [OR] 0.54, 95% confidence interval [CI] 0.32–0.95, p = 0.025), the presence of intraretinal cysts at baseline (OR 2.95, 95% CI 1.67–5.20, p < 0.001) and subretinal fluid at baseline (OR 3.17, 95% CI 1.62–6.18, p = 0.002). The sensitivity and specificity of the baseline OCT features were: baseline intraretinal cysts: (sensitivity: 54.2%, specificity: 65.2%) and subretinal fluid: (sensitivity: 85.5%, specificity: 28.3%).

Using these factors, the receiver operating characteristic ROC curve is shown in Fig. 1, with an area under the curve of 0.666 (95% CI 0.60–0.74).

OCT features of disease activity
At baseline, all 281 patients had at least one feature of fluid on OCT, which included subretinal fluid (229 eyes, 81.5%), intraretinal fluid (188 eyes, 66.9%) and intraretinal cysts (135 patients, 48.0%). After 3 consecutive anti-VEGF injections, 163 patients (58.0%) were found to have at least one feature of fluid on OCT. The proportion of features of disease activity on OCT at 12 weeks were subretinal fluid: 103 eyes (36.7%), intraretinal fluid: 95 eyes (33.8%), and intraretinal cysts: 74 eyes (26.3%).

The presence of intraretinal cysts and intraretinal fluid at baseline significantly affected mean final BCVA. Among those with intraretinal cysts at baseline, mean final BCVA was 0.69 compared to 0.43 for those without cysts (p < 0.001). Patients with intraretinal fluid at baseline had significantly worse final BCVA compared to those without intraretinal fluid (0.62 vs. 0.43, p < 0.001). There were no significant differences in VA at 3 months among patients with or without subretinal fluid at baseline (mean VA 0.56 vs. 0.55, p = 0.901).

The proportion of patients with persistent intraretinal cysts at 3 months was significantly lower among patients

Table 1 Baseline characteristics of patients

|                      | All patients |
|----------------------|--------------|
| Age (years)          | 77.7 ± 9.0   |
| Gender (%)           |              |
| Males                | 168 (59.8%)  |
| Females              | 113 (40.2%)  |
| Race (%)             |              |
| Chinese              | 264 (94.0%)  |
| Malay                | 7 (2.5%)     |
| Indian               | 5 (1.8%)     |
| Others               | 5 (1.8%)     |
| Diagnosis (%)        |              |
| Neovascular AMD      | 221 (78.6%)  |
| PCV                  | 60 (21.4%)   |
| VA (ETDRS letters)   | 54.5 ± 40.5  |
| Central retinal thickness (μm) | 442.4 ± 192.9 |
| Features of activity on OCT |          |
| Intraretinal fluid   | 188 (66.9%)  |
| Intraretinal cysts   | 135 (48.0%)  |
| Subretinal fluid     | 229 (81.5%)  |
| Pigment epithelial detachment | 274 (97.5%) |

AMD age related macular degeneration, OCT optical coherence tomography, PCV polypoidal choroidal vasculopathy, VA visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study
### Table 2: Comparison of baseline characteristics based on disease activity at month 3

| Characteristic                  | Persistent activity | No activity | P value |
|---------------------------------|---------------------|-------------|---------|
| Age (years)                     | 78.0 ± 8.3          | 77.1 ± 10.4 | 0.459   |
| Gender                          |                     |             | 0.067   |
| Male                            | 114 (63.7%)         | 48 (52.2%)  |         |
| Female                          | 65 (36.3%)          | 44 (47.8%)  |         |
| Race                            |                     |             | 0.598   |
| Chinese                         | 169 (94.4%)         | 85 (92.4%)  |         |
| Malay                           | 4 (2.2%)            | 3 (3.3%)    |         |
| Indian                          | 4 (2.2%)            | 1 (1.1%)    |         |
| Others                          | 2 (1.1%)            | 3 (3.3%)    |         |
| Diagnosis                       |                     |             | 0.838   |
| nAMD                            | 142 (79.3%)         | 72 (78.3%)  |         |
| PCV                             | 37 (20.7%)          | 20 (21.7%)  |         |
| VA (ETDRS letters)              | 53.5 ± 39.0         | 56.5 ± 41.0 | 0.384   |
| Central retinal thickness (μm)  | 458.5 ± 192.5       | 430.56 ± 189.5 | 0.279 |
| Intraretinal fluid              |                     |             | 0.626   |
| Yes                             | 122 (68.2%)         | 60 (65.2%)  |         |
| No                              | 57 (31.8%)          | 32 (34.8%)  |         |
| Intraretinal cysts              |                     |             | 0.002   |
| Yes                             | 97 (54.2%)          | 32 (34.8%)  |         |
| No                              | 82 (45.8%)          | 60 (65.2%)  |         |
| Subretinal fluid                |                     |             | 0.007   |
| Yes                             | 153 (85.5%)         | 66 (71.7%)  |         |
| No                              | 26 (14.5%)          | 26 (28.3%)  |         |
| Pigment epithelial detachment   |                     |             | 0.412   |
| Yes                             | 174 (97.2%)         | 90 (97.8%)  |         |
| No                              | 5 (2.8%)            | 2 (2.2%)    |         |

### Table 3: Predictors of persistent disease activity

| Characteristic                  | Univariate Odds ratio (95% C.I.) | P value | Multivariate Odds ratio (95% C.I.) | P value |
|---------------------------------|----------------------------------|---------|-----------------------------------|---------|
| Age (years)                     | 1.01 (0.98–1.04)                 | 0.459   |                                   | 0.281   |
| Gender (%)                      | **0.62 (0.37–1.04)**             | **0.067**| **0.54 (0.32–0.93)**              | **0.025**|
| Race (%)                        | 0.82 (0.51–1.33)                 | 0.427   |                                   | 0.385   |
| Diagnosis (%)                   | 0.94 (0.51–1.73)                 | 0.838   |                                   | 0.541   |
| VA                              | 1.33 (0.70–2.51)                 | 0.385   |                                   | 0.932   |
| Central retinal thickness       | 1.00 (1.00–1.01)                 | 0.279   |                                   | 0.314   |
| Intraretinal fluid              | 1.14 (0.67–1.94)                 | 0.626   |                                   | 0.114   |
| Intraretinal cysts              | **2.22 (1.32–3.73)**             | **0.002**| **2.95 (1.67–5.20)**              | **< 0.001**|
| Subretinal fluid                | **2.32 (1.25–4.30)**             | **0.007**| **3.17 (1.62–6.18)**              | **0.002**|
| Pigment epithelial detachment   | 0.77 (0.15–4.06)                 | 0.412   |                                   | 0.425   |
receiving ranibizumab or aflibercept compared to the group receiving bevacizumab (17.0% vs. 32.5%, \( p = 0.004 \)). Similarly, the proportion of patients with persistent intraretinal fluid at 3 months was significantly lower among patients receiving ranibizumab or aflibercept compared to the group receiving bevacizumab (25.0% vs. 39.6%, \( p = 0.011 \)). There was no difference in the proportion of patients with persistent subretinal fluid between the treatment groups.

**Discussion**

In this study of real-world outcomes among a cohort of patients with nAMD and PCV, we found that 66.1% of patients still had persistent disease activity after the initial 3 loading doses of anti-VEGF agents. The significant predictive factors for persistent disease activity at 3 months were male gender, and the presence of intraretinal cysts and subretinal fluid on OCT at baseline. These factors may serve as biomarkers that predict the likelihood of persistent activity after an initial loading dose of anti-VEGF agents.

The features of disease activity detected using OCT decreased by 41.6% (from 100% to 58.0%) after treatment with 3 consecutive loading doses of anti-VEGF agents. Among OCT features, intraretinal cysts and intraretinal fluid at baseline significantly affected the final BCVA, whereas the presence of subretinal fluid did not.

The majority of large randomized clinical trials report their primary study outcomes at 6 or 12 months, with some follow-ups extending to 24 months or longer. There are, however, few studies that focus in detail on the interim outcomes and proportion of disease activity at 3 months, after the initial 3 loading dose of anti-VEGF agents. Similarly, studies reporting factors affecting clinical outcome typically examine the effects of the various risk factors at 12 months, with few studies reporting the factors affecting the initial 3-month outcomes.

It is useful to examine the factors affecting the early treatment response, because studies have demonstrated that the initial treatment response to anti-VEGF treatment in nAMD could be helpful to predict the long term visual and anatomical outcomes of treatment. Bloch et al. [4] reported that visual acuity at month 3 was the strongest predictor of final visual acuity at month 12. Predictive factors for BCVA \( \leq 35 \) letters after 12 months were BCVA \( \leq 35 \) letters at baseline and month 3 (\( p < 0.0001 \)) while BCVA \( \geq 70 \) letters at month 12 was associated with BCVA \( \geq 70 \) letters at baseline and month 3 (\( p < 0.001 \)) and with total lesion size \( < 4 \) disc areas (\( p = 0.0147 \)). Similarly, Lai et al. [5] reported that persistence of intraretinal cysts at month 12 was associated with the persistence of non-resolved cysts at month 3, after the initial loading dose.

Baseline morphological features seen on OCT have been shown to predict final outcomes in some post hoc analysis of clinical trials. In a post hoc analysis of the VIEW study [19], morphologic features on OCT at baseline such as intraretinal cysts, subretinal fluid and pigment epithelial detachments significantly correlated with change in visual acuity at week 52. It was found that intraretinal cysts and pigment epithelial detachment at baseline were associated with reduced final vision gain, while subretinal fluid confers a protective effect and was associated with better vision gain.

Similarly, the current study has demonstrated that the features of disease activity on OCT decreased by over 40% following the initial 3 loading doses of anti-VEGF. Two specific baseline OCT features – the presence of intraretinal cysts and subretinal fluid – were predictive for persistent disease activity.

In this study, the presence of subretinal fluid at baseline did not significantly affect BCVA, which supports the findings in some studies which have suggested that the presence of persistent subretinal fluid following treatment in patients with nAMD may not adversely affect visual outcomes [19].

Interestingly, treatment with both ranibizumab and aflibercept resulted in lower proportion of eyes with persistent intraretinal cysts and intraretinal fluid at 3 months, compared to the group treated with bevacizumab, suggesting that these drugs may have a stronger treatment effect in the initial treatment period.

Extrapolating the results from major randomized clinical trials, the gain in BCVA after 3 loading doses ranges from 3.0 to 7.5 [20–22]. In our study, we observed a 3
letter gain in the cohort of nAMD and PCV patients. Hence, the visual gain in this study appears to be at the lower end of the reported range for several clinical trials on nAMD and PCV.

Among real-world studies, the AURA study reported a gain of 4.0 letters at week 12 among patients who received a loading dose [23]. A retrospective study of 279 patients with nAMD treated with ranibizumab reported a gain of 4.7 letters at 3 months compared to baseline [4].

Similarly, “real world” anatomical results on OCT are less ideal than that reported in clinical trials. In our cohort, CSFT decreased by a mean of 93.3 μm at week 12. In the CATT and PIER studies, CSFT was reported to decrease by approximately 70 to 175 μm at week 12 in nAMD patients [20, 21]. In the EVEREST 2 and PLAN ET studies, CRT decreased by approximately 75 to 130 μm in PCV patients [12, 24].

It is recognized that the clinical outcomes achieved in major clinical trials are usually better compared to real-world studies. The potential reasons include lower number of injections in real-world studies due to difficulty in scheduling injections, loss to follow up, lack of compliance and heavy patient load.

The strengths of this study include the inclusion of a large number of patients from an Asian population. This allows us to evaluate and understand the real-world outcomes of anti-VEGF outside an artificially controlled setting of a clinical trial. The risk factors identified for persistent disease activity may also be of use in the prognostication of patients. These findings can help clinicians identify potential high-risk patients for whom a more rigorous treatment regimen and follow-up can be planned. Furthermore, there is a good balance of nAMD and PCV cases in the local population that allows us to investigate the outcome of anti-VEGF monotherapy in PCV cases. Grading of images both for confirmation of diagnosis of nAMD and PCV, as well as the presence of disease activity, were performed by experienced graders from a Central Reading Center and using standardized diagnostic and grading protocols.

This study is not without limitations. The inherent limitations of a retrospective study such as selection bias due to non-randomised treatment, and potential loss to follow up.

Conclusion
Baseline OCT features such as the presence of intraretinal cysts and subretinal fluid are predictive of persistent disease activity. This may aid clinicians in identifying patients at risk for closer monitoring and more aggressive therapy.

Abbreviations
VEGF: Vascular endothelial growth factor; nAMD: Neovascular age-related macular degeneration; OCT: Optical coherence tomography; BCVA: Best-corrected visual acuity; OR: Odds ratio; CI: Confidence interval; AMD: Age-related macular degeneration; PCV: Polypoidal choroidal; FA: Fluorescein angiography; ICGA: Indocyanine green angiography; CSFT: Central subfield retinal thickness; VA: Visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study

Acknowledgements
Mr. Shiva Patil was an employee of Novartis Singapore and was involved in the initial conceptualization of the study.

Authors’ contributions
CST and LWL contributed equally to this work and were involved in the conceptualisation and writing of this manuscript. WKN was involved in the analysis and interpretation of study data. PP, CS, WKC and NS were all involved in the production of the manuscript. All authors read and approved the final manuscript.

Funding
Nil

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to restrictions under the Personal Data Protection Act 2012, Singapore, but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the institutional review board of the National Healthcare Group and conformed to the tenets of the Declaration of Helsinki. Waiver of informed consent was granted by the IRB.

Consent for publication
Not applicable.

Competing interests
Dr. Tan reports grants from National Medical Research Council (NMRC/TA/0039/2015 and NMRC Centre Grant Programme (CGAug16M012)), grants from National Healthcare Group, honoraria and non-financial support from Bayer, non-financial support from Heidelberg Engineering, honoraria and non-financial support from Novartis. Dr. Lim has no financial interests to declare. Dr. Ngo reports non-financial support from Allergan, honoraria from Bayer and honoraria from Novartis. Mr. Pandiyan and Mr. See have no financial interests to declare. Mr. Saxena is an employee of Novartis Singapore.

Author details
1Fundus Image Reading Centre, National Healthcare Group Eye Institute, Singapore, Singapore. 2National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore. 3Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. 4Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. 5Novartis (Singapore) Private Limited, Singapore, Singapore.

Received: 6 June 2020 Accepted: 22 July 2020
Published online: 06 August 2020

References
1. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PTV, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–72.
2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900–1.
3. Androudi S, Distriridou A, Pharmakakis N, Stefaniotou M, Kalogeropoulos C, Symeonidis C, et al. Guidelines for the Management of wet age-Related Macular Degeneration: recommendations from a panel of Greek experts. Adv Ther. 2016;33(7):265–76.
4. Bloch SB, la Cour M, Sander B, Hansen LKH, Fuchs J, Lund-Andersen H, et al. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol. 2013;91(1):42–7.
5. Lai T-T, Hsieh Y-T, Yang C-M, Ho T-C, Yang C-H. Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study. Sci Rep. 2019;9:529.

6. Tan CS, Lim LW, Ngo WK, Lim TH. EVEREST report 5: clinical outcomes and treatment response of polypoidal choroidal vasculopathy subtypes in a multicenter, randomized controlled trial. Invest Ophthalmol Vis Sci. 2018;59(9):890–96.

7. Tan CSH, Ngo WK, Lim LW, Lim TH. A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes. Br J Ophthalmol. 2014 Nov;98(11):1528–33.

8. Tan CS, Lim TH, Hariprasad SM. Current Management of Polypoidal Choroidal Vasculopathy. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):786–91.

9. Tan CSH, Ngo WK, Lim LW, Tan NW, Lim TH. EVEREST study report 4: fluorescein angiography features predictive of polypoidal choroidal vasculopathy. Clin Exp Ophthalmol. 2019;47(5):614–20.

10. Tan CS, Hariprasad SM, Lim LW. New paradigms in Polypoidal Choroidal vasculopathy management: the impact of recent multicenter, randomized clinical trials. Ophthalmic Surg Lasers Imaging Retina. 2018;49(1):4–10.

11. Tan CS, Ngo WK, Chen JP, Tan NW, Lim TH, Koh A, et al. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99(5):624–8.

12. Koh A, Lai TYY, Takahashi K, Wong TY, Chen L-J, Rueamviboonsuk P, et al. Efficacy and safety of Ranibizumab with or without Verteporfin photodynamic therapy for Polypoidal Choroidal vasculopathy. JAMA Ophthalmol. 2017;135(11):1206–13.

13. Tan CSH, Cheong KK, Lim LW, Li KZ. Topographic variation of choroidal and retinal thicknesses at the macula in healthy adults. Br J Ophthalmol. 2014;98(3):339–44.

14. Tan CSH, Cheong KK. Macular Choroidal thicknesses in healthy adults—relationship with ocular and demographic factors. Invest Ophthalmol Vis Sci. 2014;55(10):6452–8.

15. Tan CS, Cheong KK, Lim LW, Sadda SR. Comparison of macular choroidal thicknesses from swept source and spectral domain optical coherence tomography. Br J Ophthalmol. 2016;100(7):995–9.

16. Tan CS, Lim LW, Chow VS, Chay IW, Tan S, Cheong KK, et al. Optical coherence tomography angiography evaluation of the Parafoveal vasculature and its relationship with ocular factors. Invest Ophthalmol Vis Sci. 2016;57(9):OCT224–34.

17. Tan CS, Duyang Y, Ruiz H, Sadda SR. Diurnal variation of Choroidal thickness in Normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53(10):6523–5.

18. Tan CS, Li KZ, Lim TH. Calculating the predicted retinal thickness from spectral domain and time domain optical coherence tomography - comparison of different methods. Graefes Arch Clin Exp Ophthalmol. 2014;252(9):1491–9.

19. Waldstein SM, Simader C, Starenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in Aflibercept and Ranibizumab therapy for Neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123(7):1521–9.

20. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.

21. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1. Am J Ophthalmol. 2008;145(2):239–48 e5.

22. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik J-F, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831–9.

23. Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–6.

24. Lee WK, Iida T, Ogura Y, Chen S-J, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET Study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7): 786–93.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.